GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease Authors: Malek Zarei, Yasamin Hajiani Published: 2026 ABSTRACT BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially developed as incretin-based therapies for the management of type 2 diabetes mellitus. Over the past decade, robust clinical and mechanistic evidence has demonstrated that their therapeutic effects extend beyond glycemic control, leading to expanding use in obesity and cardiometabolic disease.MethodsThis narrative review synthesizes evidence from randomized controlled trials, cardiovascular and kidney outcome studies, meta-analyses, and real-world data, complemented by mechanistic and translational studies where relevant. Evidence across organ systems was critically appraised with attention to study design, outcome relevance, heterogeneity, and clinical certainty.ResultsGLP-1RAs consistently induce clinically meaningful weight loss and reduce major adverse cardiovascular events, while slowing the progression of chronic kidney disease in both diabetic and non-diabetic populations. These benefits are supported by large outcome trials and appear only partially attributable to improvements in glycemic control or body weight alone. In contrast, evidence supporting additional effects in metabolic liver disease and obstructive sleep apnea is moderate but evolving, whereas data on immune modulation, skeletal health, neuroprotection, and neuropsychiatric outcomes are largely derived from mechanistic, biomarker-based, observational, or preclinical studies and remain heterogeneous.ConclusionGLP-1 receptor agonists have transitioned from glucose-lowering therapies to cornerstone agents in cardiometabolic disease management. While their efficacy in obesity, cardiovascular risk reduction, and kidney protection is well established, proposed benefits in other organ systems should be interpreted cautiously and in the context of variable evidence strength. Future research should prioritize long-term safety, durability of benefit, and adequately powered trials designed to clarify disease-modifying potential beyond established cardiometabolic indications. Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were originally developed as incretin-based therapies for the treatment of type 2 diabetes mellitus (T2DM), designed to overcome the short half-life of endogenous GLP-1 while preserving its glucose-dependent insulinotropic effects. More recently, incretin-based therapy has expanded beyond selective GLP-1 receptor agonism to include dual agonists, most notably glucose-dependent insulinotropic polypeptide receptor agonists (GIP/GLP-1RA), such as tirzepatide. Although these agents share overlapping metabolic effects, they are pharmacologically distinct and should not be considered interchangeable across all mechanistic and clinical contexts [1]. By improving glucose-dependent insulin secretion and suppressing glucagon release, GLP-1RAs improve glycemic control without increasing hypoglycemia risk. In parallel, both GLP-1RAs and dual incretin agonists have demonstrated clinically meaningful effects on body weight and cardiometabolic risk, thereby expanding the therapeutic landscape from glucose lowering toward multisystem metabolic disease management [1, 2]. Importantly, these receptors are widely expressed across multiple organ systems, including the cardiovascular system, kidneys, central nervous system, gastrointestinal tract, and skeletal tissues, providing a mechanistic basis for effects extending beyond glucose regulation [3, 4]. The recognition that GLP-1RAs induce clinically meaningful and sustained weight loss marked a pivotal shift in their therapeutic positioning. Obesity, a central driver of insulin resistance, T2DM progression, and cardiometabolic disease, is often exacerbated by traditional glucose-lowering therapies; in contrast, GLP-1RAs consistently promote weight reduction while improving metabolic parameters [5, 6]. Beyond pharmacological approaches, regenerative strategies such as mesenchymal stem cell therapy have also been explored as disease-modifying interventions in T2DM, targeting insulin resistance, β-cell dysfunction, and chronic low-grade inflammation [7]. This dual glycemic and weight-lowering profile prompted large-scale investigation of GLP-1RAs in populations without diabetes, leading to regulatory approval of liraglutide, semaglutide, and tirzepatide (GIP/GLP-1RA) for chronic weight management and catalyzing rapid expansion of clinical use [5, 6]. Beyond obesity and glycemic control, cardiovascular and kidney outcome trials have demonstrated that several GLP-1RAs reduce major adverse cardiovascular events (MACE) and slow the progression of chronic kidney disease, effects that appear only partially attributable to improvements in HbA1c or body weight [8]. These findings repositioned GLP-1RAs as cardiorenal-metabolic agents and stimulated investigation into additional therapeutic domains, including metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, osteoarthritis, polycystic ovary syndrome, neurodegenerative disorders, and neuropsychiatric conditions [6, 9]. Despite this rapid clinical expansion, important challenges remain. Long-term safety, durability of benefit, weight regain after discontinuation, reductions in lean mass, cost, and equitable access continue to shape clinical decision-making and policy discussions [10]. Moreover, emerging indications are supported by heterogeneous levels of evidence, ranging from robust randomized trials to early-phase or preclinical data, underscoring the need for balanced interpretation and rigorous evaluation. Accordingly, the strength of evidence across domains varies substantially, from well-established Phase 3 clinical outcomes in cardiometabolic disease to predominantly preclinical and hypothesis-generating data in emerging areas such as neuroprotection, immunomodulation, and reproductive endocrinology. The extra-glycemic effects of GLP-1RAs can be conceptually organized into three tiers: established (cardiovascular, metabolic), emerging (renal, hepatic), and exploratory (neurocognitive, immunological). In this narrative review, we synthesize current evidence on the expanding role of GLP-1 receptor agonists (GLP-1RAs) beyond glycemic control, integrating established clinical indications, emerging therapeutic applications, safety considerations, and future research directions to provide a comprehensive and critical overview of this rapidly evolving drug class [4, 11]. Given the heterogeneous evidence supporting the extra-glycemic effects of GLP-1RAs across organ systems, Table 1 summarizes the strength and clinical certainty of available data, ranging from well-established cardiometabolic outcomes to emerging indications supported primarily by mechanistic and exploratory studies. Table 1Strength of clinical evidence supporting extra-glycemic effects of selective GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonistsDomainType of evidenceKey clinical outcomeClinical certaintyPredominant agent classObesityLarge dedicated obesity RCTs (STEP, SURMOUNT programs)Percentage body-weight reductionHighGLP-1RAs and dual GIP/GLP-1 agonistsCardiovascular outcomesCardiovascular outcome trials (CVOTs); SELECT trialMajor adverse cardiovascular events (MACE)HighPredominantly GLP-1RAs (emerging data for oral GLP-1RA and dual agonists)Kidney protectionDedicated kidney outcome trials (FLOW)eGFR slope; albuminuria progressionHighPredominantly GLP-1RAsMASLD/MASHPhase 2–3 biopsy-based randomized controlled trialsHistologic resolution of steatohepatitisModerateGLP-1RAs and dual GIP/GLP-1 agonistsObstructive sleep apneaRandomized controlled trials (SURMOUNT-OSA)Apnea–hypopnea index (AHI) reductionModerate–HighPredominantly dual GIP/GLP-1 agonistSkeletal healthBMD and bone-turnover biomarker studies; observational dataChanges in BMD and bone-turnover markersLow–ModeratePredominantly GLP-1RAsImmunomodulationMechanistic and biomarker-based human studiesInflammatory and immune biomarker modulationLow–ModeratePredominantly GLP-1RAsNeuroprotectionPreclinical models; secondary clinical outcomesNeurodegenerative and ischemic surrogate outcomesLowPredominantly GLP-1RAs (limited dual-agonist data)Neuropsychiatric effectsObservational studies; pharmacovigilance dataMood, anxiety, and behavioral outcomesLowPredominantly GLP-1RAsPolycystic ovary syndromeSmall randomized controlled trials and meta-analysesInsulin sensitivity and ovulatory functionLow–ModeratePredominantly GLP-1RAs Table 1Strength of clinical evidence supporting extra-glycemic effects of selective GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonistsDomainType of evidenceKey clinical outcomeClinical certaintyPredominant agent classObesityLarge dedicated obesity RCTs (STEP, SURMOUNT programs)Percentage body-weight reductionHighGLP-1RAs and dual GIP/GLP-1 agonistsCardiovascular outcomesCardiovascular outcome trials (CVOTs); SELECT trialMajor adverse cardiovascular events (MACE)HighPredominantly GLP-1RAs (emerging data for oral GLP-1RA and dual agonists)Kidney protectionDedicated kidney outcome trials (FLOW)eGFR slope; albuminuria progressionHighPredominantly GLP-1RAsMASLD/MASHPhase 2–3 biopsy-based randomized controlled trialsHistologic resolution of steatohepatitisModerateGLP-1RAs and dual GIP/GLP-1 agonistsObstructive sleep apneaRandomized controlled trials (SURMOUNT-OSA)Apnea–hypopnea index (AHI) reductionModerate–HighPredominantly dual GIP/GLP-1 agonistSkeletal healthBMD and bone-turnover biomarker studies; observational dataChanges in BMD and bone-turnover markersLow–ModeratePredominantly GLP-1RAsImmunomodulationMechanistic and biomarker-based human studiesInflammatory and immune biomarker modulationLow–ModeratePredominantly GLP-1RAsNeuroprotectionPreclinical models; secondary clinical outcomesNeurodegenerative and ischemic surrogate outcomesLowPredominantly GLP-1RAs (limited dual-agonist data)Neuropsychiatric effectsObservational studies; pharmacovigilance dataMood, anxiety, and behavioral outcomesLowPredominantly GLP-1RAsPolycystic ovary syndromeSmall randomized controlled trials and meta-analysesInsulin sensitivity and ovulatory functionLow–ModeratePredominantly GLP-1RAs Strength of clinical evidence supporting extra-glycemic effects of selective GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists Pharmacology and evolution of GLP-1RAs GLP-1RAs are incretin-based therapies developed to mimic the actions of endogenous GLP-1, a hormone with potent metabolic effects but an extremely short physiological half-life. The initial pharmacological objective of this drug class was to overcome the rapid degradation of native GLP-1; however, GLP-1RAs have since evolved into one of the most influential therapeutic classes in modern metabolic medicine. The first clinically approved agent, exenatide, derived from the Gila monster peptide exendin-4, received FDA approval in 2005, marking the beginning of the incretin era in diabetes pharmacotherapy [12, 13]. Subsequent drug development led to structurally and pharmacokinetically distinct GLP-1RAs, broadly categorized into short-acting and long-acting formulations. Short-acting agents such as lixisenatide exert pronounced effects on gastric emptying, thereby improving postprandial glucose control [14]. In contrast, long-acting analogues, including liraglutide and dulaglutide, provide sustained receptor activation, resulting in more stable glycaemic control and broader systemic effects. Dulaglutide has demonstrated cardiovascular benefit in outcome trials [15]. While liraglutide gained approval for both T2DM and obesity, and is currently under investigation for neurodegenerative and metabolic liver diseases [5]. Semaglutide further expanded the therapeutic landscape of GLP-1RAs through its availability in both injectable and oral formulations. This agent has demonstrated potent effects on body weight reduction, significant lowering of cardiovascular event risk, and slowing of chronic kidney disease progression, thereby reinforcing the class transition from glucose-lowering drugs to multisystem therapies [10]. At the mechanistic level, GLP-1Ras enhance glucose-dependent insulin secretion and suppress glucagon release, while also influencing gastrointestinal motility and central appetite regulation through well-characterized peripheral and hypothalamic pathways. Beyond these metabolic actions, emerging mechanistic and translational evidence suggests additional anti-inflammatory and anti-atherogenic effects, which are discussed in subsequent sections in relation to specific organ systems [12, 16]. For conceptual clarity, classical GLP-1 receptor agonists (e.g., exenatide, liraglutide, semaglutide, dulaglutide, and lixisenatide) should be distinguished from newer dual incretin agonists such as tirzepatide, which combines GIP and GLP-1 receptor activity. Throughout this review, evidence is therefore interpreted according to whether it derives from selective GLP-1 receptor agonism or dual incretin co-agonism. The pharmacological evolution of this class culminated in the development of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By simultaneously activating both incretin pathways, tirzepatide produces synergistic insulinotropic and weight-loss effects, achieving greater reductions in HbA1c and body weight than earlier GLP-1RAs. These effects are accompanied by additional improvements in blood pressure, lipid profiles, and the severity of obstructive sleep apnea (OSA) [16, 17]. Beyond glycaemic control, GLP-1RAs have now demonstrated clinical benefits across a wide spectrum of cardiometabolic conditions, including atherosclerotic cardiovascular disease (CVD) (LEADER, SUSTAIN-6, REWIND), heart failure with preserved ejection fraction (STEP-HFpEF), diabetic kidney disease (FLOW trial), and chronic weight management (STEP and SURMOUNT programs). More recently, regulatory approval has expanded to include moderate-to-severe obstructive sleep apnea, reflecting the growing recognition of GLP-1RAs as systemic disease-modifying agents [4, 10]. Collectively, current guidelines recommend GLP-1RAs not only as glucose-lowering therapies but as integrated cardiorenal–metabolic agents with broad indications spanning diabetes, obesity, cardiovascular prevention, kidney protection, and emerging neurologic and hepatic applications [18–20]. This multidimensional therapeutic profile has positioned GLP-1RAs among the most impactful pharmacological innovations of the past two decades. Figure 1 provides an organ-based overview of the extra-glycemic effects of GLP-1RAs discussed in the following sections, highlighting domains with robust clinical evidence versus emerging indications. Fig. 1Extra-glycemic effects of GLP-1RAs across organ systems. This schematic overview summarizes the organ-specific effects of GLP-1RAs beyond glycemic control. Robust clinical evidence supports benefits in obesity, cardiovascular disease, and chronic kidney disease, whereas effects in hepatic, respiratory, immune, skeletal, and neurocognitive domains are supported by moderate to emerging levels of clinical evidence Extra-glycemic effects of GLP-1RAs across organ systems. This schematic overview summarizes the organ-specific effects of GLP-1RAs beyond glycemic control. Robust clinical evidence supports benefits in obesity, cardiovascular disease, and chronic kidney disease, whereas effects in hepatic, respiratory, immune, skeletal, and neurocognitive domains are supported by moderate to emerging levels of clinical evidence Integrated mechanistic framework of GLP-1–based multisystem effects The expanding clinical profile of GLP-1–based therapies is best understood within an integrated mechanistic framework that connects central appetite regulation, peripheral metabolic remodeling, immune modulation, and tissue-specific receptor signaling. Rather than representing isolated organ-level effects, the cardiovascular, renal, hepatic, skeletal, and neurobehavioral outcomes observed with GLP-1 receptor agonists (GLP-1RAs) and dual incretin agonists arise from a set of interdependent biological pathways that operate concurrently and often synergistically [21, 22]. At the core of this framework lies a central–peripheral axis in which GLP-1 receptor signaling in the hypothalamus and brainstem regulates satiety, food intake, and energy balance. Pharmacologic activation of these pathways leads to sustained reductions in caloric intake and body weight, which in turn drive improvements in insulin sensitivity, blood pressure, lipid profiles, and systemic inflammatory tone [22, 23]. These centrally mediated effects represent a major contributor to the broad cardiometabolic benefits observed in clinical trials, particularly in obesity-focused populations treated with higher-dose semaglutide or tirzepatide [24, 25]. In parallel, an inflammation–adipose tissue axis provides a complementary pathway linking metabolic dysfunction to multisystem disease. Adipose tissue expansion and dysfunction promote chronic low-grade inflammation, which contributes to atherosclerosis, renal injury, and hepatic steatosis. GLP-1–based therapies have been shown to attenuate this inflammatory milieu by reducing circulating cytokine levels, modulating macrophage polarization, and improving adipose tissue biology [26, 27]. Notably, these anti-inflammatory effects are not fully explained by weight loss alone and likely involve weight-independent mechanisms [10, 27]. Beyond systemic metabolic effects, accumulating evidence supports direct tissue-level actions of GLP-1 receptor signaling. GLP-1 receptors are expressed in multiple peripheral organs, including the cardiovascular system, kidney, liver, and central nervous system. Experimental and translational studies indicate that GLP-1 signaling can improve endothelial function, enhance nitric oxide bioavailability, modulate myocardial substrate utilization, influence renal hemodynamics, and reduce hepatic lipid accumulation [28–31]. These direct actions provide a mechanistic basis for organ-specific benefits that are not fully explained by changes in glycemic control or adiposity and may represent weight-independent effects. Within this integrated model, a key interpretive distinction is the relative contribution of weight-dependent versus weight-independent effects. In some clinical domains, such as obstructive sleep apnea and obesity-related heart failure, therapeutic benefits appear to be largely mediated by reductions in body weight [25, 32]. In contrast, cardiovascular outcome trials have demonstrated reductions in major adverse cardiovascular events that are not fully proportional to weight loss and persist after adjustment for glycemic changes, supporting the presence of additional direct and systemic mechanisms [33, 34]. Similarly, renal and hepatic benefits likely reflect a combination of metabolic, hemodynamic, and anti-inflammatory effects, only partially attributable to adiposity reduction [30, 35]. Extending beyond traditional metabolic endpoints, emerging evidence suggests that GLP-1 receptor signaling may also influence neurobehavioral and reward-related processes. Preclinical studies demonstrate that activation of GLP-1 receptors within mesolimbic pathways can attenuate dopaminergic signaling and reduce both food- and alcohol-seeking behavior, linking metabolic regulation with reward circuitry [36]. Early human data, including analyses of appetite control and eating behavior, support a potential role in modulating hedonic feeding, although these findings remain heterogeneous and largely exploratory [37]. Accordingly, these neurobehavioral effects should be interpreted as hypothesis-generating rather than definitive. From a translational perspective, the multisystem effects of GLP-1–based therapies can be broadly classified into three mechanistic categories: predominantly weight-dependent effects, mixed weight-dependent and weight-independent effects, and primarily weight-independent receptor-mediated or cellular effects. Weight-dependent effects are most evident in obesity-related obstructive sleep apnea, mechanical load–related osteoarthritis, and some improvements in blood pressure and cardiometabolic risk factors. Mixed effects are best supported in cardiovascular, renal, and hepatic outcomes, where clinical benefits appear to reflect the combined influence of adiposity reduction, hemodynamic changes, anti-inflammatory signaling, and direct tissue-level GLP-1 receptor pathways. In contrast, neurobehavioral, immunomodulatory, and some cellular stress-response effects are more plausibly weight-independent, but these remain supported mainly by preclinical, biomarker-based, or early-phase translational evidence rather than definitive outcome trials. Importantly, the strength of evidence supporting these categories varies substantially, ranging from robust randomized clinical trial data in cardiometabolic outcomes to predominantly preclinical or early-phase evidence in neurobehavioral and immunomodulatory domains. This framework provides a unifying basis for interpreting multisystem outcomes and should be considered when evaluating domain-specific evidence throughout this review. A schematic overview of this integrated framework is presented in Fig. 2. Fig. 2Integrated framework of GLP-1RA multisystem effects. GLP-1 receptor agonists exert effects across multiple organ systems through predominantly weight-dependent, mixed, and weight-independent mechanisms. The strength of evidence varies across domains, with robust clinical data in cardiometabolic outcomes and predominantly preclinical or early-phase evidence in emerging areas such as neuroprotection, immunomodulation, and reproductive endocrinology Integrated framework of GLP-1RA multisystem effects. GLP-1 receptor agonists exert effects across multiple organ systems through predominantly weight-dependent, mixed, and weight-independent mechanisms. The strength of evidence varies across domains, with robust clinical data in cardiometabolic outcomes and predominantly preclinical or early-phase evidence in emerging areas such as neuroprotection, immunomodulation, and reproductive endocrinology GLP-1RAs in obesity management The magnitude, durability, and consistency of weight loss observed in randomized clinical trials and post-marketing data rapidly repositioned GLP-1RAs from glucose-lowering agents to cornerstone pharmacotherapies for obesity, including in individuals without diabetes [38]. Obesity is now recognized as a chronic, multifactorial disease characterized by excess adiposity that impairs health and substantially increases the risk of cardiometabolic disorders and several malignancies. Its global prevalence has risen sharply over recent decades, imposing a growing burden on healthcare systems [39, 40]. Robust evidence from large randomized clinical trials and meta-analyses supports the efficacy of GLP-1RAs in obesity management. Parallel to the expanding clinical evidence base, real-world utilization of GLP-1RAs has increased markedly. Claims-based analyses report a rise in GLP-1 prescriptions among U.S. adults from approximately 0.9% in 2019 to nearly 4% in 2024, while survey data indicate that a substantial proportion of users receive these agents primarily for weight reduction rather than glycaemic control [41, 42]. Regulatory approvals followed these trends, with liraglutide approved for chronic weight management in 2014, semaglutide in 2021, and tirzepatide in 2023 [10, 38]. Mechanistically, GLP-1RAs induce weight loss predominantly through coordinated central and peripheral pathways. These mechanisms include brainstem–hypothalamic circuits governing satiety, as well as vagal afferent signaling initiated by gastric mechanoreceptor activation during feeding that converges on central appetite-regulating centers. Delayed gastric emptying and altered gastrointestinal motility further reduce hunger and caloric intake, supporting sustained negative energy balance [43]. Consistent with these biological mechanisms, comparative clinical evidence suggests robust and agent-differentiated effects on anthropometric outcomes. Meta-analytic data show significant reductions in body weight, body mass index (BMI), and waist circumference across multiple GLP-1RAs, including efpeglenatide, exenatide, liraglutide, and semaglutide, with the largest average weight-loss signal observed with semaglutide [44]. This degree of weight loss substantially exceeds the typical 5–10% plateau observed with lifestyle interventions alone, a threshold beyond which additional metabolic and cardiovascular benefits become more pronounced [45, 46]. Semaglutide 2.4 mg once weekly has demonstrated clinically meaningful weight reduction in adults with obesity without diabetes when combined with lifestyle intervention. In the STEP-1 trial, participants achieved a mean weight loss of 14.9% from baseline, accompanied by favorable changes in cardiometabolic risk markers and body composition [34]. Tirzepatide further extended the efficacy range in SURMOUNT-1, producing substantial dose-dependent reductions in body weight alongside improvements in fat mass, lipid profiles, blood pressure, and fasting insulin levels [47]. Importantly, the efficacy of semaglutide for weight reduction has been consistently demonstrated across diverse populations and clinical contexts, including East Asian cohorts, individuals with prediabetes, and patients with obesity-related conditions such as knee osteoarthritis, suggesting the generalizability of STEP trial findings beyond Western populations [48, 49]. The contemporary obesity pharmacotherapy landscape is increasingly shaped by incretin-based multi-agonism. Network meta-analyses suggest a stepwise gradient of weight-loss efficacy from GLP-1 monotherapy to dual and then triple incretin agonists [50]. Within this framework, phase 3 trials support tirzepatide 15 mg as a high-efficacy option, achieving approximately 22.5% weight loss, while retatrutide has been reported to approach 24% weight reduction at 48 weeks in selected datasets, magnitudes that approach those observed with bariatric surgical interventions [47, 51]. Despite their effectiveness, GLP-1–based therapies should be contextualized within the broader obesity pharmacotherapy armamentarium. Alternative FDA-approved agents, including orlistat, phentermine, topiramate, naltrexone–bupropion, and setmelanotide for rare monogenic obesity, generally produce more modest weight loss, typically in the range of 3–9% of baseline body weight, compared with the 15–20% often observed with GLP-1–based therapies and co-agonists [6, 52]. These agents also carry distinct tolerability limitations, such as higher rates of psychiatric or cognitive adverse effects with phentermine–topiramate and blood-pressure concerns with naltrexone–bupropion. Network meta-analytic comparisons highlight treatment discontinuation due to adverse events as a notable limitation for some non–GLP-1 regimens. In contrast, GLP-1RAs are predominantly associated with gastrointestinal adverse events and demonstrate comparatively favorable psychiatric and cardiovascular safety profiles in these analyses [53, 54]. A clinically important and sometimes underrecognized issue in pharmacologic weight loss is a change in body composition. Imaging-based sub-studies using DXA and MRI suggest that a substantial proportion of total weight lost with semaglutide and tirzepatide, often estimated at 25–45%, reflects reductions in lean mass. Although this pattern is directionally similar to lifestyle-induced weight loss, it may have implications for physical function, resting energy expenditure, and the risk of sarcopenic obesity in vulnerable populations [55, 56]. Accordingly, mitigation strategies such as resistance training, adequate protein intake, and investigational adjuncts, including myostatin inhibitors and selective androgen receptor modulators, have been proposed to preserve lean mass during GLP-1–mediated weight reduction, though these approaches remain under active evaluation [57, 58]. However, long-term functional consequences and clinical significance of these changes remain uncertain. Weight regain following treatment discontinuation represents another critical challenge, reinforcing obesity as a chronic disease requiring long-term management rather than short-course therapy [59]. In the STEP-1 extension study, participants regained a substantial proportion of lost weight, reported at approximately 68%, within one year of semaglutide discontinuation, with many cardiometabolic benefits reverting toward baseline over the same period [60]. Similarly, STEP-4 demonstrated that continued semaglutide therapy led to additional weight loss, whereas treatment withdrawal resulted in clinically meaningful regain, supporting maintenance therapy as the default strategy for sustained benefit [60]. In addition to weight reduction, semaglutide has been shown to promote reversion to normoglycemia in individuals with obesity and prediabetes, highlighting its potential role in modifying early dysglycemic trajectories [49]. As GLP-1–based obesity pharmacotherapy expands, safety considerations beyond gastrointestinal tolerability require careful evaluation, particularly with respect to skeletal health [61]. Weight loss itself can adversely affect bone turnover and density, and bariatric surgery, especially malabsorptive procedures, is associated with well-documented skeletal complications. Whether GLP-1RA–induced weight loss carries similar or distinct skeletal risks remains incompletely defined. Preclinical studies suggest that liraglutide may improve certain bone material properties despite weight loss, although these findings often involve exposures exceeding typical clinical doses and evidence for semaglutide remains limited [61]. Human data are sparse, as most trials were conducted in diabetes populations, rarely prioritized bone endpoints, and had limited follow-up, underscoring the need for dedicated skeletal outcome studies in obesity populations treated with GLP-1RAs and emerging multi-agonists [61]. Importantly, no fracture-powered randomized trials have been conducted in this context. Finally, contemporary guidelines increasingly support the integration of GLP-1RAs into structured obesity-care pathways, particularly in individuals with obesity-related comorbidities or elevated cardiovascular risk. Nevertheless, optimal sequencing with lifestyle interventions, long-term adherence strategies, and durability of benefit remain central challenges in real-world implementation [62]. Overall, the weight-loss effects of GLP-1RAs represent predominantly weight-dependent mechanisms that underpin many downstream clinical benefits (see Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects"). Cardiovascular protection with GLP-1RAs Within the integrated framework outlined in Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effect", cardiovascular outcomes represent a domain with strong clinical evidence and mixed weight-dependent and weight-independent mechanisms. Diabetes mellitus is a major driver of CVD, which has prompted regulatory requirements for cardiovascular outcome trials (CVOTs) to assess the safety and efficacy of glucose-lowering therapies. These trials primarily evaluate three-point MACE, defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. Robust evidence from large CVOTs and meta-analyses supports the cardioprotective effects of GLP-1RAs. Early CVOTs investigating GLP-1RAs, including LEADER, HARMONY Outcomes, REWIND, and SUSTAIN-6, established cardiovascular safety and demonstrated cardioprotective effects for liraglutide, albiglutide, dulaglutide, and semaglutide in patients with T2DM [15, 33, 63]. Evidence from PIONEER 6 extended these findings to oral semaglutide, supporting cardiovascular safety and consistency across formulations, while the recently reported SOUL trial further supported cardiovascular benefit in a high-risk population [64, 65]. Subsequent pooled analyses and meta-analyses strengthened this evidence base. Large-scale systematic reviews encompassing more than 60,000 participants across randomized placebo-controlled trials demonstrated a consistent reduction in MACE of approximately 12–14% with GLP-1RA therapy, alongside additional benefits for cardiovascular mortality, all-cause mortality, hospitalization for heart failure, and stroke. Importantly, these effects were consistent across subgroups defined by baseline CVD status, renal function, age, body mass index, and degree of glycaemic control [66–68]. Notably, cardiovascular protection with GLP-1RAs extends beyond glycaemic lowering alone. Although reductions in HbA1c correlate with improved cardiovascular outcomes in diabetic populations, meta-analytic evidence indicates that MACE reduction persists after accounting for glycaemic effects, suggesting that these effects are not fully explained by glycaemic or weight-related changes and likely involve additional weight-independent mechanisms such as blood pressure reduction and anti-inflammatory actions [69–71]. Over time, CVOT design evolved from predominantly secondary-prevention cohorts toward inclusion of high-risk primary-prevention populations. Earlier trials enrolled patients with a high prevalence of established CVD, whereas later studies, such as REWIND, included a majority of participants without prior cardiovascular events. Despite these differences, pooled analyses demonstrated no significant interaction between baseline CVD status and the magnitude of MACE reduction [15, 33, 63, 72]. Evidence for cardiovascular benefit has also expanded beyond diabetes. The SELECT trial demonstrated that high-dose semaglutide significantly reduced MACE in individuals with overweight or obesity and established CVD but without diabetes, leading to regulatory approval for cardiovascular risk reduction in this population. This finding provided the first large-scale evidence supporting the cardiovascular benefit of an anti-obesity pharmacotherapy in a non-diabetic cohort [73–75]. Agent-specific CVOTs reveal heterogeneity within the GLP-1RA class. Semaglutide and liraglutide demonstrated significant reductions in MACE, with semaglutide’s benefit largely driven by reductions in non-fatal stroke and MI, and liraglutide showing additional reductions in cardiovascular and all-cause mortality. Dulaglutide reduced MACE predominantly in a primary-prevention–leaning population, with stroke as a major contributor, whereas lixisenatide demonstrated cardiovascular safety without superiority. Albiglutide showed marked MACE reduction before its withdrawal for non-clinical reasons [15, 21, 63, 64, 76–78]. Beyond atherosclerotic outcomes, GLP-1RAs exert favorable effects on heart failure–related endpoints. Meta-analyses demonstrate modest reductions in hospitalization for heart failure, and recent trials in heart failure with preserved ejection fraction (HFpEF) have shown significant improvements in symptoms, exercise capacity, inflammatory markers, and heart-failure–related events in patients with obesity treated with semaglutide or tirzepatide. These findings suggest a potential disease-modifying role for incretin–based therapies in obesity-related heart failure, although longer-term outcome data remain limited [66, 79–82]. Mechanistic and translational evidence provide biological plausibility for these clinical observations. GLP-1RAs improve multiple cardiometabolic risk factors, including systolic blood pressure, body weight, lipid profiles, and inflammatory tone, while modestly increasing heart rate. At the tissue level, GLP-1 receptor signaling modulates endothelial function, nitric oxide bioavailability, inflammatory pathways, myocardial substrate utilization, and ischemic conditioning, collectively contributing to cardiovascular protection, consistent with the integrated mechanisms described in Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects" [53, 83, 84]. Experimental evidence from diabetic models further supports the central role of nitric oxide dysregulation in endothelial dysfunction and cardiovascular pathology under conditions of metabolic stress [85]. Emerging data further suggest potential roles for GLP-1RAs in vascular and aortic disease. These observations are predominantly derived from preclinical and early-phase studies. Preclinical and early clinical studies indicate that GLP-1RAs suppress vascular inflammation, inhibit matrix metalloproteinase activity, preserve extracellular matrix integrity, and promote anti-inflammatory macrophage phenotypes, with possible benefits in aortic aneurysm progression and peripheral artery disease. Although clinical validation remains limited, these findings extend the cardiovascular relevance of GLP-1RAs beyond classical coronary outcomes [86–90]. Finally, contemporary clinical guidelines now reflect this body of evidence. The American Diabetes Association, American College of Cardiology, and European Society of Cardiology endorse GLP-1RAs for cardiovascular risk reduction in patients with T2DM and elevated cardiovascular risk, while KDIGO guidelines recommend GLP-1RAs as preferred add-on therapy after SGLT2 inhibitors in patients with diabetes and chronic kidney disease, emphasizing their cardiovascular advantages [91–94]. Overall, the cardiovascular benefits of GLP-1RAs appear to be only partially explained by weight loss and are likely driven by a combination of weight-dependent and weight-independent mechanisms (see Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects"). GLP-1RAs in obstructive sleep apnea Within this framework, improvements in OSA are predominantly weight-dependent. OSA is a highly prevalent sleep-related breathing disorder characterized by recurrent episodes of upper airway obstruction during sleep, resulting in intermittent hypoxia, sympathetic activation, and sleep fragmentation. Obesity represents one of the strongest modifiable risk factors for OSA, and key components of its pathophysiology, including upper airway collapsibility, parapharyngeal fat deposition, and impaired ventilatory control, are closely linked to excess adiposity [95]. Clinical evidence for GLP-1–based therapies in OSA is emerging and currently limited to a small number of randomized controlled trials. Given the potent weight-reducing effects of GLP-1RAs, their potential therapeutic role in OSA has attracted increasing attention. Early clinical studies with liraglutide demonstrated modest reductions in the apnea–hypopnea index (AHI). However, these improvements were less pronounced than those achieved with continuous positive airway pressure (CPAP), which remains the gold-standard therapy for OSA [96]. A major advance emerged with the development of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Two pivotal randomized controlled trials enrolling 469 adults with moderate-to-severe OSA and obesity, but without diabetes, demonstrated a mean reduction of approximately 55% in AHI, corresponding to 25–30 fewer apneas or hypopneas per hour compared with placebo [97, 98]. Based on these findings, tirzepatide received FDA approval on December 20, 2024, representing the first pharmacologic therapy approved for moderate-to-severe OSA in adults with obesity [99]. Beyond reductions in AHI, tirzepatide produced clinically meaningful improvements in disease status. Across trials, 42–50% of treated participants achieved clinical remission or transitioned to mild OSA, compared with only 14–16% in placebo groups [97, 98, 100]. Importantly, among participants not receiving positive airway pressure therapy, tirzepatide remained effective, reducing AHI by 27.4 events per hour versus 4.8 events per hour with placebo, suggesting substantial disease modification even in the absence of mechanical respiratory support [100]. Improvements in OSA with GLP-1–based therapies appear to be predominantly weight-dependent, although additional weight-independent mechanisms have been proposed. Weight loss reduces upper airway collapsibility by decreasing parapharyngeal and tongue fat deposition [97, 101]. In parallel, weight-independent mechanisms have been proposed, including enhanced upper airway dilator muscle function, reduced systemic inflammation and airway edema, improved central respiratory control, and favorable alterations in sleep architecture, particularly increased slow-wave sleep [9, 102–104]. Semaglutide is also under investigation for the treatment of OSA. Preliminary data suggest potential improvements in sleep-related parameters and metabolic contributors to airway obstruction; however, robust randomized controlled evidence remains limited, and current data are largely exploratory, and definitive conclusions await ongoing and future trials [102, 105]. Taken together, GLP-1RAs and tirzepatide (GIP/GLP-1RA) in particular represent a promising advance in the management of obesity-associated OSA. The SURMOUNT-OSA trials demonstrate that targeted metabolic therapy can meaningfully reduce OSA severity and modify upper airway physiology, supporting a novel, disease-modifying approach that complements existing mechanical and behavioral treatments. In this context, improvements in OSA severity with GLP-1–based therapies appear to be predominantly weight-dependent, with potential additional contributions from weight-independent mechanisms. Kidney protection with GLP-1RAs Within this framework, renal outcomes reflect a combination of weight-dependent and direct intrarenal mechanisms supported by evolving clinical evidence. Diabetic kidney disease (DKD) remains one of the most common and devastating complications of T2DM and a major contributor to global morbidity and mortality. Despite substantial advances in renoprotective therapy, including renin–angiotensin–aldosterone system (RAAS) blockade and, more recently, sodium–glucose cotransporter 2 (SGLT2) inhibitors and finerenone, a considerable proportion of patients continue to experience progressive kidney function decline, persistent albuminuria, and elevated cardiovascular risk. Consequently, increasing attention has focused on therapeutic strategies that provide organ protection beyond glycaemic control, including GLP-1RAs [4]. Evidence for renal protection with GLP-1RAs has evolved from secondary endpoints in CVOTs to dedicated kidney outcome trials. Evidence accumulated over the past decade indicates that GLP-1RAs confer clinically meaningful kidney benefits through a combination of direct renal effects and indirect metabolic mechanisms that are, at least in part, independent of glucose lowering. Across large CVOTs, kidney endpoints, although secondary, consistently favored GLP-1RA therapy. Trials such as LEADER, SUSTAIN-6, REWIND, ELIXA, EXSCEL, HARMONY, and AMPLITUDE-O incorporated composite renal outcomes that typically included new-onset macroalbuminuria, sustained decline in estimated glomerular filtration rate (eGFR), doubling of serum creatinine, progression to kidney replacement therapy, or renal death. Meta-analyses of these trials demonstrated a 17–21% reduction in composite renal outcomes, with the most pronounced effect observed for prevention of new-onset macroalbuminuria, corresponding to an approximate 25% risk reduction compared with placebo [66, 106]. However, these early trials were not powered to evaluate hard kidney outcomes, and uncertainty persisted regarding the ability of GLP-1RAs to meaningfully delay progression to end-stage kidney disease (ESKD) or improve survival in chronic kidney disease (CKD) populations. A 2021 meta-analysis incorporating data from AMPLITUDE-O provided greater clarity, demonstrating a 21% reduction in composite renal outcomes, although reductions in hard kidney endpoints, such as doubling of serum creatinine, ≥ 40% eGFR decline, or ESKD, did not reach statistical significance [66]. More granular insights emerged from post-hoc analyses of LEADER and SUSTAIN-6. These analyses showed that GLP-1RA therapy was associated with a slower annual rate of eGFR decline, particularly among individuals with baseline eGFR < 60 mL/min/1.73 m². A pooled analysis estimated that semaglutide slowed eGFR decline by approximately 0.59 mL/min/1.73 m² per year compared with placebo, with a more pronounced effect, approximately 1.06 mL/min/1.73 m² per year, observed in patients with established CKD [107, 108]. Persistent reductions in albuminuria also emerged as a clinically relevant surrogate. In LEADER, patients achieving a > 30% reduction in urinary albumin-to-creatinine ratio (UACR) experienced a 33% lower risk of kidney events and an 18% reduction in MACE, independent of baseline albuminuria [109]. The AWARD-7 trial provided particularly important evidence in patients with moderate-to-severe CKD (stages 3–4). In this population, dulaglutide significantly slowed eGFR decline compared with insulin glargine over 52 weeks (− 0.7 vs. −3.3 mL/min/1.73 m²). Among individuals with macroalbuminuria, dulaglutide reduced the risk of ≥ 40% eGFR decline or kidney failure by approximately 75% (hazard ratio 0.25) [110, 111]. Notably, this trial provided important evidence suggesting that a GLP-1RA may preserve kidney function in advanced CKD without excess adverse effects beyond predictable gastrointestinal intolerance. A decisive shift in the field occurred with the FLOW trial, the first dedicated kidney outcomes trial of a GLP-1RA. In patients with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73 m²), semaglutide 1 mg once weekly reduced the composite endpoint of kidney failure, substantial loss of kidney function, and kidney- or cardiovascular-related death by 24%, and lowered UACR by approximately 40% relative to baseline [112]. Over two years, eGFR decline was slowed by more than 3 mL/min/1.73 m² compared with placebo, with consistent effects across creatinine- and cystatin C–based estimations. These benefits were observed regardless of concomitant SGLT2 inhibitor use, although the number of patients receiving SGLT2 inhibitors was limited [113]. Collectively, FLOW strengthened the evidence for renoprotective effects of GLP-1RAs. Evidence of kidney benefit also extends beyond diabetes. In the SELECT trial, semaglutide reduced persistent eGFR decline among adults with overweight or obesity and established CVD but without diabetes [114]. This observation aligns with meta-analytic findings demonstrating that GLP-1RAs slow eGFR decline in individuals with baseline eGFR 30–60 mL/min/1.73 m² regardless of diabetes status [115]. Together, these findings suggest the potential expansion of GLP-1RA use to non-diabetic CKD populations. Real-world evidence provides additional supportive data beyond randomized trials. In a large observational cohort of individuals with diabetes and acute kidney injury, GLP-1RA use was associated with lower mortality (6.8% vs. 12.9%), fewer major adverse cardiovascular events, and a reduced incidence of major adverse kidney events compared with non-users [116]. Similarly, a large target trial emulation involving 140,169 adults with obesity without diabetes reported a 36% reduction in major adverse kidney events and nearly a 50% reduction in all-cause mortality among GLP-1RA initiators compared with users of other anti-obesity medications [117]. Across meta-analyses, renal benefits with GLP-1RAs appear consistent. A pooled analysis of 11 trials, including 85,373 participants, demonstrated an 18% reduction in composite kidney outcomes and a 16% reduction in kidney failure [118, 119]. Another meta-analysis of seven trials reported a 17% reduction in composite renal outcomes and a 25% reduction in new-onset macroalbuminuria, reinforcing albuminuria lowering as a class effect [106]. Mechanistically, the renal benefits of GLP-1RAs are multifactorial. Proposed direct intrarenal mechanisms include inhibition of sodium–hydrogen exchanger 3 (NHE3) in proximal tubules, leading to natriuresis and reduced intraglomerular pressure; anti-inflammatory effects mediated through suppression of NF-κB signaling and NLRP3 inflammasome activation; improved endothelial nitric oxide bioavailability; attenuation of oxidative stress; and potential modulation of renal fibrosis, consistent with mechanisms outlined in Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects" [119, 120]. GLP-1RAs may also promote mitochondrial biogenesis and improve cellular energetics, contributing to preservation of nephron structure. Indirect effects, including weight loss, blood pressure reduction, lipid improvement, and reduced hypoglycaemia, further mitigate hyperfiltration, albuminuria, and progressive kidney injury. In advanced CKD and dialysis populations, available evidence remains limited but suggests that GLP-1RAs can be used safely for glycaemic and weight control without major adverse renal effects. Small studies report stable eGFR trajectories and improved metabolic parameters, although benefits for hard kidney endpoints in ESKD remain uncertain [121, 122]. Data on kidney transplant recipients and individuals with type 1 diabetes are sparse and inconclusive. These findings are based on small studies with limited follow-up. Combination therapy with SGLT2 inhibitors is biologically appealing due to complementary hemodynamic, metabolic, anti-inflammatory, and antifibrotic mechanisms. Modeling studies suggest that combined use of GLP-1RAs, SGLT2 inhibitors, and RAAS blockade may produce additive reductions in CKD progression and cardiovascular risk, although clinical outcome data remain limited [123]. Ongoing and future trials will clarify optimal sequencing and synergy in clinical practice. Despite substantial progress, important knowledge gaps persist. The precise mechanisms of renal protection are incompletely defined; evidence in non-diabetic CKD and advanced kidney disease remains limited; and comparative effectiveness among individual GLP-1RAs and dual agonists such as tirzepatide continues to evolve. Ongoing studies, including FLOW extension analyses, REMODEL, SOUL, TREASURE-CKD, and SURPASS-CVOT, are expected to refine these insights and further delineate the role of GLP-1–based therapies in kidney disease management [120, 124]. In this context, renal benefits of GLP-1RAs likely reflect a combination of weight-dependent and weight-independent mechanisms, including direct intrarenal effects (see Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects"). GLP-1RAs in steatotic liver disease (MASLD) Within this framework, hepatic effects are largely weight-dependent, with additional direct metabolic and anti-inflammatory contributions. Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease, is characterized by hepatic steatosis in the absence of secondary causes such as significant alcohol consumption, viral hepatitis, or steatogenic medications, and is increasingly recognized as a hepatic manifestation of systemic cardiometabolic dysfunction [125]. MASLD and T2DM demonstrate a well-established bidirectional relationship, whereby each condition exacerbates the risk, severity, and progression of the other, reflecting shared pathophysiological drivers including insulin resistance, adipose tissue dysfunction, and chronic low-grade inflammation [126]. Current management strategies prioritize sustained lifestyle modification and optimization of cardiometabolic comorbidities; however, relatively few pharmacological interventions have demonstrated consistent histologic benefit, among which GLP-1RAs have emerged as a leading evidence-supported option [127]. Evidence for GLP-1RAs in MASLD is derived from phase 2–3 trials with histologic endpoints, although data on fibrosis outcomes remain limited. Evidence from biopsy-based clinical trials indicates that GLP-1RAs are associated with reproducible reductions in hepatic steatosis and increased rates of steatohepatitis resolution, while effects on fibrosis outcomes appear more heterogeneous and likely influenced by baseline fibrosis stage and treatment duration. Importantly, histologic resolution of steatohepatitis does not necessarily translate into meaningful fibrosis regression, which remains a distinct and more challenging therapeutic endpoint with direct prognostic and regulatory implications. In early proof-of-concept studies, the phase 2 LEAN trial demonstrated that liraglutide improved key histologic features, including reductions in steatosis and fibrosis and a higher likelihood of steatohepatitis resolution in patients with non-alcoholic steatohepatitis [128–130]. Among GLP-1RAs, semaglutide has shown particularly strong efficacy signals, with dose-dependent increases in steatohepatitis resolution in MASLD/MASH populations [130, 131]. In larger semaglutide trials, weekly semaglutide 2.4 mg was associated with steatohepatitis resolution without worsening of fibrosis in approximately two-thirds of treated patients, compared with roughly one-third in placebo groups at 72 weeks, supporting a clinically meaningful histologic effect beyond isolated biochemical improvement [130–132]. Importantly, these benefits are not confined to individuals with diabetes; pooled analyses in non-diabetic populations suggest reductions in liver fat and improvements in liver enzymes, although evidence in advanced fibrosis and cirrhosis remains limited and warrants targeted investigation [133]. Beyond GLP-1 monotherapy, incretin-based co-agonist therapies are increasingly shaping the treatment landscape for steatotic liver disease. Although tirzepatide has been less extensively studied in MASLD than semaglutide, available data indicate meaningful reductions in absolute liver fat content. In biopsy-confirmed MASH with stage F2–F3 fibrosis, tirzepatide produced significant placebo-adjusted improvements in steatohepatitis resolution without fibrosis worsening, with dose-dependent response rates and the highest dose achieving resolution in approximately 60% of patients compared with around 10% in placebo-treated individuals at 52 weeks [47, 134, 135]. Similarly, emerging dual agonists such as survodutide (glucagon/GLP-1 receptor agonist) have reported high rates of histologic improvement without fibrosis worsening in phase 2 studies, supporting the hypothesis that multi-agonist pharmacology may enhance reductions in liver fat and inflammatory activity in MASH [136, 137]. From a mechanistic perspective, the hepatic benefits of GLP-1–based therapies appear to be predominantly weight-dependent, with additional contributions from weight-independent pathways. While weight loss plausibly contributes to reductions in steatosis and secondary hepatic inflammation, several non-glycemic mechanisms appear biologically relevant, including improvements in insulin sensitivity, attenuation of systemic inflammatory signaling, and suppression of hepatic de novo lipogenesis and gluconeogenesis (see integrated framework in Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects") [138]. Additional mechanisms may involve favorable modulation of adipose tissue biology, including increased adiponectin levels and normalization of lipolysis, thereby reducing the flux of circulating free fatty acids to the liver [28]. At the intrahepatic signaling level, GLP-1RAs have been proposed to suppress de novo lipogenesis through AMPK activation and inhibition of SREBP-1c, while enhancing fatty acid oxidation via PPARα upregulation, collectively shifting hepatic metabolic flux away from lipotoxic pathways [130, 139, 140]. Taken together, available clinical data indicate that GLP-1RAs, particularly semaglutide 2.4 mg weekly, are associated with consistent and clinically relevant rates of steatohepatitis resolution without fibrosis worsening, while emerging incretin-based co-agonists such as tirzepatide and glucagon/GLP-1 dual agonists may further enhance histologic response rates in biopsy-confirmed MASH, including patients with moderate-to-advanced fibrosis [130, 141]. These findings are based on early-phase trials and require confirmation in larger, long-term studies. Nonetheless, important uncertainties remain regarding efficacy, safety, and tolerability in cirrhosis and advanced fibrosis, where altered portal hemodynamics, nutritional vulnerability, and drug exposure may modify the risk–benefit profile. Accordingly, future trials specifically enriched for these populations and powered for fibrosis regression and clinical outcomes are required before GLP-1–based therapies can be regarded as disease-modifying treatments across the full MASLD spectrum [133]. Overall, improvements in MASLD appear to be largely mediated by weight loss, with additional contributions from direct metabolic and anti-inflammatory mechanisms. Skeletal and joint effects of GLP-1RAs From a mechanistic perspective, skeletal and joint outcomes with GLP-1RAs largely reflect weight-dependent processes. The skeletal and joint effects of GLP-1RAs must be interpreted within the context of intentional weight loss, a process known to influence bone metabolism and fracture risk. To date, human evidence remains limited, with most clinical studies focusing on changes in bone mineral density and markers of bone turnover rather than fracture outcomes, which are rarely designated as primary endpoints in major obesity trials. While preclinical studies suggest potential direct skeletal actions of GLP-1 receptor signaling, the extent to which these findings translate into clinically meaningful effects at therapeutic doses in humans remains uncertain. Evidence for skeletal and joint effects of GLP-1RAs is limited and derived primarily from preclinical studies and secondary outcomes in clinical trials. Intentional weight loss, whether achieved through caloric restriction, bariatric surgery, or pharmacological therapy, is consistently associated with measurable alterations in bone metabolism, providing an essential context for interpreting the skeletal effects of GLP-1RAs [142]. Human studies of calorie restriction demonstrate that moderate weight loss is accompanied by increases in bone turnover markers and reductions in bone mineral density (BMD), most notably at the total hip, while lumbar spine BMD tends to be relatively preserved [143, 144]. These skeletal effects appear to be dependent on the magnitude of weight reduction, with evidence suggesting that clinically relevant changes typically emerge once body weight loss exceeds approximately 7–10% [145, 146]. Importantly, bone loss may persist or progress even after weight stabilization, particularly among postmenopausal women, indicating that weight loss–associated skeletal alterations are not invariably transient [145]. More pronounced skeletal deterioration has been consistently reported following bariatric and metabolic surgery, characterized by high-turnover bone loss, marked reductions in hip BMD, deterioration of bone microarchitecture, and increased long-term fracture risk [147–149]. These adverse outcomes are thought to reflect the combined effects of mechanical unloading, nutritional deficiencies, loss of lean mass, and substantial alterations in gut hormone and adipokine signaling [142]. Against this background, GLP-1RAs represent a distinct weight-loss paradigm that integrates metabolic improvement with receptor-mediated signaling, raising the question of whether their skeletal effects diverge from those observed with lifestyle- or surgery-induced weight loss. Initial mechanistic insights into GLP-1 signaling and bone homeostasis were derived from preclinical models. GLP-1 receptor knockout mice exhibit reduced trabecular bone mass, increased osteoclast activity, and impaired biomechanical strength [150]. In rodents, GLP-1 receptor activation stimulates calcitonin secretion from thyroid C cells, and the skeletal phenotype observed in knockout models has therefore been partially attributed to reduced calcitonin-mediated inhibition of bone resorption [151, 152]. Complementary in vitro studies indicate that GLP-1RAs, particularly liraglutide, promote osteoblast differentiation, reduce osteoblast apoptosis, and suppress osteoclast formation through activation of PI3K/Akt, MAPK, and cAMP/PKA/β-catenin signaling pathways, suggesting a potential uncoupling of bone formation from resorption in experimental settings [153–155]. Consistent with these cellular observations, multiple animal models of osteoporosis and diabetes have shown that liraglutide and semaglutide increase trabecular BMD and improve microarchitectural parameters, even in the setting of pharmacologically induced weight loss [156, 157]. However, these skeletal benefits were most evident at doses substantially exceeding those approved for obesity treatment in humans, and gains in bone strength or fracture resistance did not uniformly accompany improvements in BMD [156, 158]. Moreover, preclinical data on semaglutide remain limited and heterogeneous, underscoring a translational gap between experimental findings and clinical application. These findings are based on experimental models and may not directly translate to clinical settings. This divergence becomes more apparent in human studies. Until recently, randomized controlled trials specifically designed to evaluate skeletal outcomes with GLP-1RAs were scarce. In older adults without diabetes but at increased fracture risk, 52 weeks of semaglutide treatment resulted in significant weight loss accompanied by increased bone resorption, reflected by elevated CTX levels, and modest reductions in BMD at the lumbar spine, total hip, and tibia [159]. These changes closely resembled those observed during calorie restriction, supporting a predominantly weight-mediated effect, and the lack of equivalent weight loss in the control group limited assessment of weight-independent drug effects [159]. Similarly, a randomized study following an initial low-calorie diet demonstrated that liraglutide monotherapy was associated with small but significant reductions in hip and spine BMD, whereas the addition of resistance exercise attenuated bone loss to an extent comparable to exercise alone [160]. Collectively, these findings suggest that, in humans, the skeletal effects of GLP-1RAs appear to be predominantly weight-dependent and largely parallel those of weight loss itself rather than reflecting a consistent intrinsic anabolic or anti-resorptive action. Meta-analyses and systematic reviews in patients with type 2 diabetes further highlight the complexity of this relationship. While some analyses report neutral effects of GLP-1RAs on BMD and fracture risk, others suggest modest, agent-specific benefits, particularly with liraglutide [161, 162]. However, substantial heterogeneity in study populations, drug selection, dosing, follow-up duration, and fracture ascertainment limits the strength of these conclusions [163, 164]. Notably, fracture outcomes have rarely been designated as primary endpoints in major obesity trials, including the STEP program, leaving the long-term fracture risk associated with GLP-1 RA–induced weight loss insufficiently defined, especially in individuals experiencing weight reductions exceeding 15–20% [34, 61]. Overall, the certainty of evidence for fracture outcomes remains low. Beyond bone metabolism, increasing attention has focused on the musculoskeletal effects of GLP-1RAs in knee osteoarthritis, a condition in which excess body weight amplifies mechanical loading, inflammation, and pain. In the STEP-9 trial, semaglutide was associated with improvements in knee pain and physical function compared with placebo in patients with obesity and moderate-to-severe knee osteoarthritis, in parallel with substantial weight loss [165, 166]. However, the absence of imaging or biochemical assessments of cartilage and subchondral bone limits interpretation, as it remains uncertain whether these benefits reflect symptomatic improvement secondary to weight reduction or direct disease-modifying effects [167]. Preclinical evidence suggests that GLP- RAs may exert anti-inflammatory and chondroprotective effects within the joint, potentially mediated through modulation of gut–joint axis signaling and intestinal farnesoid X receptor pathways [168, 169]. Nevertheless, current human data predominantly support improvements in pain and function rather than definitive structural modification of osteoarthritic joints. However, Current evidence does not support definitive structural joint modification. Taken together, available evidence indicates that GLP-1RAs induce skeletal changes that largely resemble those associated with intentional weight loss, including modest reductions in BMD and transient increases in bone resorption, particularly in the absence of concurrent exercise [61, 170]. Although preclinical studies suggest potential bone-protective and joint-modulating mechanisms, these effects have not been consistently replicated in humans at clinically relevant doses. Accordingly, long-term, adequately powered trials incorporating fracture outcomes, advanced imaging, and comprehensive musculoskeletal endpoints are required to determine whether GLP-1RAs confer clinically meaningful benefits on bone and joint health beyond their established effects on body weight and metabolic control [9, 61, 167, 170]. In this context, skeletal and joint effects of GLP-1RAs appear to be predominantly weight-dependent, with limited evidence supporting clinically relevant weight-independent mechanisms. Immunomodulatory effects of GLP-1RAs These observations are most consistent with weight-independent mechanisms, although the supporting evidence remains largely preclinical and hypothesis-generating. The immunomodulatory effects of GLP-1RAs have attracted increasing interest as potential contributors to their cardiovascular and metabolic benefits. Current evidence is predominantly derived from mechanistic and preclinical studies, demonstrating consistent anti-inflammatory actions across multiple immune cell types and signaling pathways. In humans, however, available data are largely derived from changes in circulating inflammatory biomarkers and translational observations, while randomized trials specifically designed around immune-mediated clinical endpoints remain limited. Accumulating evidence suggests that the favorable cardiovascular outcomes observed with GLP-1RAs, may be partially mediated through anti-inflammatory mechanisms that extend beyond glucose-lowering alone [33, 63, 171]. Immune modulation has similarly emerged as a therapeutic target in non-pharmacological and regenerative approaches for diabetes, including mesenchymal stem cell–based therapies, which aim to attenuate chronic inflammation and restore immune–metabolic homeostasis [7]. Both preclinical and clinical investigations demonstrate that GLP-1 and its pharmacological agonists attenuate vascular and systemic inflammation, thereby reducing atherosclerosis-associated immune activation and overall inflammatory burden [172]. At the cellular level, GLP-1 receptor activation has been shown to reduce monocyte adhesion to the vascular endothelium and limit macrophage infiltration into inflamed vascular tissues, attenuating early inflammatory events that contribute to cardiovascular pathology [173, 174]. In experimental models of sepsis, liraglutide significantly reduced systemic inflammatory responses and improved survival, effects that were absent in GLP-1 receptor–deficient animals, supporting a receptor-dependent immunomodulatory mechanism [175, 176]. Beyond effects on immune cell recruitment, GLP-1RAs exert anti-oxidative and cytokine-modulating actions. Native GLP-1, as well as agents such as exenatide and liraglutide, reduce reactive oxygen species generation in endothelial cells and circulating monocytes/macrophages, contributing to suppression of redox-sensitive inflammatory signaling [177, 178]. In parallel, these agents consistently decrease the production of key pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, and are associated with reductions in circulating C-reactive protein levels in human studies, highlighting a systemic anti-inflammatory profile [179, 180]. At the molecular level, GLP-1 receptor signaling interferes with central inflammatory pathways. Activation of the cAMP/PKA axis inhibits nuclear factor-κB (NF-κB) signaling through suppression of the IκB kinase complex, thereby limiting transcription of multiple pro-inflammatory genes [181, 182]. In addition, GLP-1RAs suppress activation of the NLRP3 inflammasome through coordinated effects on priming signals, oxidative stress reduction, enhancement of mitochondrial quality control, and PKA-mediated modulation of inflammasome assembly [183, 184]. Direct immunomodulatory effects of GLP-1 receptor signaling have been described across multiple immune cell populations. In macrophages, GLP-1 receptor activation promotes a phenotypic shift from pro-inflammatory M1 toward anti-inflammatory M2 polarization, involving STAT6 activation and metabolic reprogramming [185, 186]. T-cell responses are similarly influenced, with GLP-1RAs suppressing effector T-cell proliferation while favoring regulatory T-cell expansion, thereby contributing to restoration of immune balance under inflammatory conditions [187, 188]. Experimental data further indicate that GLP-1 receptor expression is dynamically regulated during immune activation. In murine models, GLP-1 receptor expression increases in activated CD4⁺ and CD8⁺ T cells, whereas genetic deletion of the receptor is associated with altered lymphocyte profiles and reduced regulatory T-cell proportions, suggesting a role for GLP-1 signaling in maintaining immune homeostasis [189, 190]. Pharmacological activation of the GLP-1 receptor has been shown to correct Th17/Treg imbalance by suppressing pro-inflammatory Th17 responses and enhancing Treg differentiation through pathways involving PI3K/Akt/FOXO1 signaling [191]. Importantly, human studies corroborate these findings, demonstrating rapid upregulation of GLP-1 receptor expression in activated naïve CD4⁺ T cells, particularly under regulatory T-cell polarization conditions, where GLP-1R expression is highest and closely associated with canonical Treg markers such as Foxp3 and CD25 [192]. These observations support a functional role for GLP-1 receptor signaling in human adaptive immunity and provide translational relevance to preclinical immunomodulatory findings. However, these findings are based on biomarker and cellular endpoints rather than clinical outcomes. Collectively, available evidence supports a model in which GLP-1RAs exert broad immunomodulatory effects by attenuating inflammatory signaling pathways, suppressing oxidative stress, modulating innate and adaptive immune cell function, and promoting regulatory immune phenotypes. These effects appear largely weight-independent and independent of glycemic control and provide a mechanistic framework for the pleiotropic benefits of GLP-1RAs across inflammatory and cardiometabolic disorders [172, 181]. Conceptually, these observations align with broader immunotherapy-based strategies in diabetes, where targeted modulation of immune pathways has been explored across different diabetes phenotypes [193]. However, these effects are largely supported by preclinical and translational evidence, and robust clinical outcome data remain limited, particularly for immune-mediated clinical endpoints. In this context, immunomodulatory effects of GLP-1RAs are best considered weight-independent but remain largely supported by preclinical and translational evidence (see Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects"). Neuroprotective effects of GLP-1RAs Within the integrated framework, these findings are best interpreted as weight-independent, although current support comes mainly from preclinical and early-phase data. The putative neuroprotective actions of GLP-1RAs have been most consistently demonstrated in experimental models of ischemic stroke and neurodegenerative diseases, where reproducible effects on neuronal survival, inflammation, and vascular integrity have been reported. In humans, evidence remains indirect and heterogeneous, primarily deriving from secondary stroke outcomes in cardiovascular outcome trials, observational analyses, and small to intermediate-sized clinical studies in selected neurological conditions. While these findings support biological plausibility, definitive evidence for disease-modifying neuroprotective efficacy in clinical practice has yet to be established [194]. Building on this predominantly preclinical evidence base, experimental studies in models of ischemic stroke and neurodegeneration have consistently reported neuroprotective effects. Across approximately 35 predominantly rodent studies of focal cerebral ischemia, GLP-1RAs were associated with reductions in infarct volume, neuronal loss, and neurological deficit scores across a range of ischemia induction paradigms and treatment windows, suggesting a broadly reproducible protective signal. Neuroprotection has been reported with multiple agents, including exendin-4, liraglutide, lixisenatide, semaglutide, recombinant GLP-1, and dual GLP-1/GIP receptor agonists, suggesting a class-related effect rather than a compound-specific phenomenon [195–197]. Importantly, beneficial effects have been observed in both hyperglycemic and normoglycemic settings. Several studies reported greater neuroprotection with GLP-1RAs compared with insulin or metformin despite comparable glycemic control, suggesting that cerebral benefits may be partly independent of glucose lowering. This glucose-independent signal strengthens the translational rationale for evaluating GLP-1RAs in acute and chronic neurological disease contexts beyond populations with diabetes [198–201]. At the cellular level, the most consistently replicated effects in ischemic brain tissue include attenuation of apoptosis and oxidative injury. Multiple studies demonstrated increased Bcl-2/Bax ratios within ischemic regions, accompanied by reduced caspase activation and downstream apoptotic markers, aligning with decreased neuronal death even when treatment was initiated after stroke onset. Parallel antioxidant effects, manifested as reduced lipid peroxidation (e.g., lower malondialdehyde levels) and increased endogenous defenses such as glutathione and superoxide dismutase, support preservation of mitochondrial function and redox homeostasis following ischemia [202–206]. Beyond direct neuronal survival, GLP-1RAs have repeatedly demonstrated neurovascular benefits in experimental stroke models. These include preservation of blood–brain barrier integrity, reduced vascular permeability, and improvements in cerebral blood flow. Several studies also reported upregulation of vascular endothelial growth factor and markers consistent with angiogenesis and neurovascular remodeling, suggesting protection and partial restoration of the neurovascular unit during post-ischemic recovery [207–210]. Evidence for engagement of restorative signaling pathways has also been reported. In rodent stroke models, GLP-1RA treatment increased markers associated with neural progenitor proliferation and early neurogenesis, including doublecortin, nestin, Ki-67, and BrdU. However, the extent to which these signals translate into mature, functionally integrated neurons appears variable across studies. Collectively, these findings are consistent with GLP-1RAs priming post-ischemic tissue for repair rather than acting solely through limitation of acute injury [211–214]. At the signaling level, multiple neuroprotective pathways have been implicated across experimental models, including cAMP/PKA/CREB, PI3K/Akt, MAPK/ERK, Wnt/β-catenin, and Nrf2/HO-1. In several studies, pharmacological antagonism or genetic knockdown of the GLP-1 receptor attenuated neuroprotection, supporting partial receptor dependence while leaving open the possibility of GLP-1R-independent contributions in specific contexts [215–218]. Clinical and translational signals are emerging but remain less definitive than the preclinical evidence. Importantly, these observations are derived largely from secondary or post hoc analyses and were not designed to test neuroprotective efficacy as a primary clinical endpoint. Large CVOTs reported significant reductions in stroke incidence with semaglutide and dulaglutide, and meta-analyses indicate a modest but consistent reduction in total stroke risk with GLP-1RA therapy. Observational real-world studies further suggest lower stroke risk compared with other glucose-lowering therapies, although findings are not uniform across datasets, reflecting residual confounding and population heterogeneity, and should be interpreted cautiously given the secondary nature of these analyses [15, 209, 219–221]. In the setting of acute ischemic stroke, early interventional studies suggest the feasibility and tolerability of exenatide without signals of worsened neurological outcomes; however, these trials were not powered to assess efficacy. Ongoing or recently completed studies such as TEXAIS and STEXAS are expected to clarify therapeutic windows, dosing strategies, and clinical relevance in the hyper-acute phase, where timing and patient selection are likely to be critical determinants of outcome [222–225]. Beyond stroke, early clinical studies in neurodegenerative diseases broadly align with experimental observations. Phase II trials in Parkinson’s disease reported potential improvements in motor and non-motor outcomes with agents including exenatide, lixisenatide, and liraglutide, while preliminary evidence in Alzheimer’s disease suggests potential attenuation of cognitive decline and structural brain changes with liraglutide. Nonetheless, larger and longer-duration trials are required to determine whether these effects reflect true disease modification [226–228]. Dual and multi-agonist incretin strategies may further modulate neuroprotection in selected experimental paradigms. Dual GLP-1/GIP receptor agonists have demonstrated reductions in infarct size, suppression of apoptotic and neuroinflammatory signaling, and improved neurological outcomes in stroke and epilepsy models. In Alzheimer’s-related models, dual agonism has been associated with restoration of brain insulin signaling, reduced tau hyperphosphorylation, and improved cognitive performance in settings of central insulin resistance. These findings motivate comparative mechanistic and translational studies rather than assumptions of universal superiority across neurological diseases [229–231]. Overall, the integrated evidence supports a biologically plausible, predominantly weight-independent neuroprotective profile of GLP-1RAs, encompassing attenuation of apoptosis and oxidative stress, preservation of neurovascular integrity, and engagement of reparative signaling pathways, together with early but still evolving clinical signals in stroke and neurodegenerative disorders. The principal remaining gap is confirmation in adequately powered, disease-specific randomized trials capable of defining optimal timing, patient selection, and clinically meaningful neurological endpoints beyond cardiometabolic outcomes, which are currently lacking [228, 232, 233]. Overall, the neuroprotective effects of GLP-1RAs are best considered weight-independent but remain largely supported by preclinical and early-phase clinical evidence. GLP-1RAs in polycystic ovary syndrome These effects can be viewed as predominantly weight-independent, with the existing evidence base largely limited to preclinical and early-stage clinical studies. Polycystic ovary syndrome (PCOS) is a heterogeneous metabolic–reproductive disorder characterized by insulin resistance, compensatory hyperinsulinemia, hyperandrogenism, and chronic ovulatory dysfunction. Given the central role of insulin resistance in amplifying ovarian androgen production and impairing folliculogenesis, GLP-1RAs have gained attention as therapeutic candidates by targeting core metabolic abnormalities underlying the syndrome [234, 235]. Clinical evidence for GLP-1RAs in PCOS is limited to small randomized trials and meta-analyses, with overall low-to-moderate certainty. Mechanistically, GLP-1RAs improve whole-body insulin sensitivity by enhancing insulin signaling in skeletal muscle, liver, and adipose tissue, while reducing hyperinsulinemia through glucose-dependent modulation of pancreatic β-cell activity. These metabolic effects are accompanied by clinically meaningful weight loss, which appears to be a major driver of downstream reproductive improvements and contributes to attenuation of insulin-driven ovarian androgen synthesis and partial restoration of reproductive endocrine balance [236, 237]. Clinical evidence from randomized controlled trials and meta-analyses indicates favorable metabolic and reproductive effects of GLP-1RAs in women with PCOS, particularly among those with overweight or obesity. A meta-analysis including women with PCOS reported that GLP-1RA therapy was associated with improvements in menstrual regularity and higher spontaneous pregnancy rates compared with metformin or placebo, suggesting potential benefits that extend beyond glycemic control [238–240]. However, the relative contribution of weight loss versus weight-independent insulin-sensitizing mechanisms to these reproductive outcomes remains incompletely resolved. More quantitative evidence is provided by larger meta-analyses. In an analysis of eight randomized trials involving 375 women with PCOS, GLP-1RAs were superior to metformin in improving insulin sensitivity and reducing body mass index, supporting a metabolic advantage in this population [240]. Similarly, a separate meta-analysis of four randomized trials demonstrated significant reductions in waist circumference, BMI, serum triglycerides, and total testosterone levels with GLP-1RA therapy compared with placebo, whereas changes in total cholesterol and HOMA-IR did not reach statistical significance [241]. These findings suggest that GLP-1RAs may exert a beneficial effect on hyperandrogenism and central adiposity even when improvements in conventional insulin resistance indices are modest. Reproductive endpoints appear particularly responsive to GLP-1RA treatment. A dedicated meta-analysis focusing on fertility-related outcomes demonstrated significant increases in natural pregnancy rates and improvements in menstrual cyclicity in women with PCOS, reinforcing the clinical relevance of metabolic–reproductive interactions in this condition [240]. Notably, these effects were observed across different GLP-1RA agents, suggesting a class effect rather than molecule-specific activity. Preclinical studies provide mechanistic support for these clinical observations. In animal models of PCOS, GLP-1RAs consistently reduced body weight, visceral adiposity, and markers of insulin resistance, while improving ovarian morphology and follicular development. In androgen-induced PCOS models, liraglutide normalized estrous cyclicity, improved granulosa and theca cell integrity, and reduced cystic follicle formation, although the magnitude of reproductive recovery was dependent on dose and treatment duration [242, 243]. Similarly, exenatide improved ovarian histology, reduced cystic follicles, and restored regular estrous cycles in insulin-resistant PCOS models, with effects comparable to or exceeding those of metformin in some experimental settings [244, 245]. At the molecular level, preclinical evidence implicates multiple signaling pathways in GLP-1RA-mediated effects in PCOS, including AMPK–SIRT1, PI3K/Akt, and steroidogenic regulatory pathways such as STAR and CYP17A1. These pathways are centrally involved in insulin sensitivity, ovarian steroidogenesis, and follicular maturation, supporting the possibility that GLP-1RAs exert both indirect metabolic effects and direct ovarian actions [244, 246]. Clinical studies with individual GLP-1RAs further substantiate their therapeutic potential. Liraglutide, administered either as monotherapy or in combination with metformin, was associated with reductions in body weight, waist circumference, and free androgen indices while increasing sex hormone-binding globulin levels in women with PCOS. Several trials also reported improvements in menstrual frequency and pregnancy outcomes, including higher cumulative pregnancy rates and improved outcomes in assisted reproductive settings when liraglutide was combined with metformin [247–252]. Importantly, some of these benefits were observed despite no differential weight loss between treatment arms, suggesting mechanisms beyond adiposity reduction. However, these observations are derived from small studies and require confirmation. Exenatide has been associated with similar benefits, including improvements in body weight, insulin resistance, androgen profiles, menstrual regularity, and ovulation rates, particularly when used in combination with metformin. In comparative trials, exenatide-based regimens were associated with higher natural pregnancy rates and superior menstrual outcomes compared with metformin monotherapy, supporting an additive role for GLP-1RA therapy in metabolically driven reproductive dysfunction [253–256]. Given the increasing use of GLP-1–based therapies in women of reproductive age with PCOS, inadvertent exposure during early pregnancy is becoming a clinically relevant concern. This risk may be amplified by improved fertility and potential reductions in oral contraceptive effectiveness due to delayed gastric emptying [257]. Current human data, derived from observational cohorts and teratology databases, have not demonstrated a consistent increase in major congenital malformations following early exposure. However, pharmacovigilance analyses have identified potential signals for adverse outcomes such as spontaneous abortion and hypertensive disorders, and most exposures occur only during early gestation. Additionally, preclinical studies have reported fetal growth restriction and structural abnormalities. However, available evidence remains limited and insufficient to establish fetal safety [258, 259]. Accordingly, appropriate preconception counseling and treatment planning are essential when prescribing these agents in this population. Most available data are observational and limited to early pregnancy exposure. Emerging data on newer GLP-1RAs further expand this therapeutic landscape. Semaglutide has been associated with substantial weight loss and favorable metabolic effects in women with PCOS and obesity, and ongoing trials are evaluating its impact on reproductive and cardiometabolic outcomes [34, 260]. Preclinical studies with dulaglutide have also shown dose-dependent reductions in ovarian insulin concentrations, androgen levels, and cystic follicle burden, alongside modulation of steroidogenic gene expression, suggesting class-wide ovarian effects [261, 262]. Despite these encouraging findings, several limitations warrant consideration. Most available studies are of relatively short duration, involve small sample sizes, and frequently lack long-term follow-up or adequately powered reproductive endpoints. The extent to which improvements in hyperandrogenism and fertility are mediated by direct ovarian mechanisms versus indirect effects of weight loss and improved insulin sensitivity remains uncertain. In addition, the use of GLP-1RAs in women of reproductive age requires careful preconception counseling and clinical monitoring [252]. Collectively, current evidence indicates that GLP-1RAs improve key metabolic, hormonal, and reproductive abnormalities in women with PCOS, particularly those with overweight or obesity. Although their efficacy appears superior to metformin for several anthropometric and androgen-related outcomes, the overall strength of evidence remains low to moderate and predominantly derived from early-phase studies, supporting their use primarily as second-line or add-on therapy following lifestyle modification and metformin. Larger, well-designed randomized trials with longer follow-up are required to clarify long-term safety, reproductive efficacy, and optimal positioning of GLP-1RAs within PCOS management algorithms [263]. In this context, the metabolic and reproductive effects of GLP-1RAs in PCOS appear to be largely weight-dependent, with uncertain contributions from direct weight-independent mechanisms. Neuropsychiatric effects of GLP-1RAs From a mechanistic perspective, these effects appear predominantly weight-independent, with evidence primarily derived from preclinical and early clinical studies. The neuropsychiatric effects of GLP-1RAs represent an evolving and actively debated area rather than an established therapeutic domain. Biological plausibility is supported by GLP-1 receptor expression in brain regions involved in mood regulation, reward processing, and stress responses, as well as by experimental data implicating effects on neuroinflammatory, neurotrophic, and metabolic neural signaling pathways. Clinically, available evidence remains mixed and largely indirect, consisting of modest changes in depression-related scales, observational and pharmacovigilance data, and secondary analyses of metabolic trials, with no large randomized studies specifically designed to evaluate psychiatric outcomes. Accordingly, while GLP-1RAs may influence neuropsychiatric phenotypes in selected contexts, their role in modifying mood or psychiatric disease trajectories has not been definitively established [264]. Evidence for neuropsychiatric effects of GLP-1RAs is limited and primarily derived from observational studies, secondary analyses, and small clinical trials. Beyond this broad evidentiary context, several biological pathways have been proposed to link GLP-1 receptor signaling with neuropsychiatric outcomes. GLP-1 receptors are expressed in brain regions implicated in mood regulation, reward processing, and stress responsivity, including the amygdala, hippocampus, prefrontal cortex, and mesolimbic dopamine system. Experimental studies further suggest that GLP-1 signaling may influence monoaminergic transmission, hypothalamic–pituitary–adrenal axis activity, neuroinflammatory pathways, oxidative stress, and neurotrophic signaling, including mechanisms related to brain-derived neurotrophic factor (BDNF) [265, 266]. Consistent with this, experimental models of neuropathic pain have demonstrated that modulation of microglial activity can influence BDNF expression and downstream inhibitory signaling pathways, including KCC2 and GABAA receptor regulation, highlighting the broader relevance of neuroimmune–neurotrophic interactions in central nervous system disorders [267].In parallel, improvements in peripheral metabolic status, such as weight loss, enhanced insulin sensitivity, and attenuation of chronic inflammation, may indirectly contribute to changes in mood and quality of life in susceptible populations [264]. Emerging human data extend GLP-1 receptor–mediated effects on mesolimbic circuitry to reward-driven behaviors. In randomized clinical trials in obesity, semaglutide and other GLP-1RAs have been associated with improvements in appetite control and reductions in hedonic eating, although these findings are not specific to psychiatric outcomes, including favorable changes in validated measures such as the Control of Eating Questionnaire (CoEQ) [37, 268]. Observational analyses further suggest potential reductions in alcohol-related behaviors among individuals treated with GLP-1–based therapies, although these findings remain indirect and hypothesis-generating [269]. Mechanistically, these effects are supported by preclinical studies demonstrating that GLP-1 receptor activation in the nucleus accumbens and related reward circuits attenuates dopaminergic signaling and reduces both food- and alcohol-seeking behavior [36, 270]. However, available human data remain heterogeneous and insufficient to support therapeutic claims in addiction or eating disorders. Clinical evidence offers cautious support for this biological rationale but stops short of definitiveness. A systematic review and meta-analysis pooling randomized and prospective studies reported a statistically significant yet modest reduction, with substantial heterogeneity across studies, in depression scale scores among adults treated with GLP-1RAs compared with controls. Similar trends were observed in individuals with type 2 diabetes, although agent-specific findings were inconsistent; for example, liraglutide appeared favorable in some subgroup analyses, while sensitivity analyses raised concerns regarding robustness and heterogeneity [271]. Large observational datasets examining healthcare utilization have also reported fewer depression- and anxiety-related visits among GLP-1RA users compared with DPP-4 inhibitor users. While such findings cannot be equated with direct symptom improvement, they lend circumstantial support to a potential benefit signal but do not establish causality [272]. At the same time, a balanced assessment requires explicit consideration of countervailing evidence. When the outcome of interest is prevention of incident depression rather than symptom improvement, results are inconsistent. A systematic review focusing on patients with diabetes identified only a small number of retrospective observational studies, with discordant findings and no randomized trials capable of supporting a prophylactic claim [273]. Moreover, selection bias is a recurrent limitation across phase-3 obesity and diabetes trials, many of which excluded individuals with major depressive disorder or suicidal ideation. Consequently, an absence of signal in controlled trials cannot be confidently extrapolated to real-world populations, particularly at higher anti-obesity doses or with longer treatment durations [274]. Real-world analyses and case-based observations further complicate the picture. In some patients, initiation of GLP-1RAs has been temporally associated with worsening depression, anxiety, or emergent suicidal ideation, with symptom improvement reported after drug discontinuation. Although causality cannot be established from such data, these patterns are clinically relevant and warrant attention rather than dismissal, although they are based on non-randomized evidence [274]. One proposed mechanistic explanation centers on reward circuitry: GLP-1 signaling may alter mesolimbic dopamine dynamics, including changes in dopaminergic neuron activity and dopamine transporter expression, potentially increasing vulnerability to anhedonia or related depressive features in susceptible individuals [264, 274]. In addition, treatment-related adverse effects, such as gastrointestinal intolerance, marked appetite suppression, or early discontinuation, may indirectly affect mood and well-being, particularly in patients with complex comorbidity or polypharmacy profiles [264, 274]. Concerns regarding suicidality illustrate the nuanced nature of the available evidence. A large active-comparator, new-user cohort study in individuals with type 2 diabetes reported higher crude rates of suicidality among GLP-1RA users compared with DPP-4 or SGLT-2 inhibitor users; however, these associations attenuated to null after adjustment for measured confounders, not supporting a clear independent risk signal in that analysis [275]. Conversely, pharmacovigilance reports and some real-world datasets have identified disproportionate reporting of suicidal ideation or depression-related events among GLP-1RA users. Such findings are inherently susceptible to reporting bias and confounding by indication and should therefore be regarded as hypothesis-generating rather than causal evidence [274]. Discrepancies between trial data and real-world observations may reflect differences in dose, patient selection, follow-up duration, baseline psychiatric risk, and outcome ascertainment [274]. Taken together, the most defensible interpretation is that GLP-1RAs may confer modest antidepressant benefits in selected settings, particularly where metabolic dysfunction and inflammation are prominent contributors to symptom burden. At the same time, these agents cannot be assumed to be uniformly mood-protective, and there are credible reasons to monitor for adverse psychiatric outcomes. Heightened vigilance may be warranted in patients with pre-existing mood or anxiety disorders, younger adults, individuals receiving higher anti-obesity doses, or those who develop new anhedonia, insomnia, anxiety, or depressive symptoms after treatment initiation [264, 271, 273, 274]. From a narrative review perspective, GLP-1RAs are best framed as biologically plausible metabolic–psychiatric bridge agents, with effects likely reflecting both weight-dependent and weight-independent mechanisms, with emerging supportive evidence, while acknowledging that definitive conclusions will require adequately powered prospective trials in psychiatric-relevant populations, stratification by metabolic phenotype, standardized psychiatric endpoints, and longer follow-up to clarify causality, dose-dependence, and subgroup-specific risk [264, 273, 274]. Overall, the neuropsychiatric effects of GLP-1RAs appear to reflect a combination of weight-dependent and weight-independent mechanisms but remain supported by limited and heterogeneous clinical evidence (see Sect. "Integrated Mechanistic Framework of GLP-1–Based Multisystem Effects"). Safety profile of GLP-1RAs Safety considerations surrounding GLP-1RAs extend beyond their well-characterized gastrointestinal tolerability profile and require careful separation of early safety concerns that were not substantiated by higher-quality evidence from adverse events that have demonstrated more consistent associations across randomized trials and real-world studies. Evidence for safety outcomes is derived from large randomized trials, meta-analyses, and real-world observational studies, with varying levels of certainty across different adverse events. Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, remain the most frequently reported class-related adverse effects. These events are typically dose-dependent and represent a major determinant of titration strategies, adherence, and treatment discontinuation, particularly during initiation and up-titration phases [5, 276]. Pancreatic safety has historically attracted substantial scrutiny. Early observational signals raised concerns regarding acute pancreatitis and pancreatic malignancy; however, large CVOTs and subsequent meta-analyses have not demonstrated a consistently increased risk of pancreatitis or pancreatic cancer associated with GLP-1 RA therapy. Collectively, these data provide the strongest available reassurance to date, although continued pharmacovigilance remains appropriate given the low incidence and long latency of some pancreatic outcomes [277–279]. A similar evidentiary trajectory applies to thyroid safety. While rodent models demonstrated C-cell hyperplasia and medullary thyroid carcinoma, large human cohort studies have not shown an increased risk of thyroid cancer over short- to mid-term follow-up. Accordingly, current prescribing recommendations continue to emphasize cautious use and contraindication in high-risk populations, despite the absence of confirmed excess risk in human studies [151, 280–282]. In contrast to these largely refuted early concerns, gallbladder and biliary disease has emerged as a relatively consistent safety signal. Meta-analyses of randomized controlled trials indicate modestly increased risks of cholelithiasis, cholecystitis, and related biliary disorders, particularly at higher doses, with longer exposure, and when GLP-1RAs are used for weight management rather than glycemic control. Although absolute risk increases are small, the association is clinically meaningful and is plausibly linked to rapid weight loss and alterations in gallbladder motility [283, 284]. Psychiatric safety warrants a similarly nuanced interpretation. Post-marketing surveillance and regulatory assessments have documented reports of depression, anxiety, insomnia, and suicidal ideation; however, spontaneous reporting systems are inherently limited by underreporting, reporting bias, and confounding by indication [285, 286]. Importantly, large population-based comparative studies have not demonstrated a consistent increased risk of suicidality with GLP-1RAs compared with DPP-4 inhibitors or SGLT-2 inhibitors after appropriate adjustment, including analyses encompassing individuals with pre-existing psychiatric disorders. These findings support a monitoring-based approach rather than assumptions of a causal psychiatric hazard [275]. Nevertheless, continued post-marketing surveillance and individualized clinical monitoring remain warranted, particularly in patients with pre-existing psychiatric vulnerability. Several emerging safety signals remain under active investigation. Observational studies have suggested a potential association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION), characterized by a small absolute risk increase and inconsistent findings across analyses. Given the rarity of events and the absence of confirmatory randomized data, NAION should currently be regarded as a hypothesis-generating observation rather than an established adverse effect or indication for treatment discontinuation [287–289]. Similarly, delayed gastric emptying associated with GLP-1RAs has prompted concerns regarding perioperative aspiration risk. While aspiration events appear uncommon and not clearly increased, higher rates of gastric content retention have led professional societies to recommend temporary withholding of therapy before elective procedures as a precautionary measure rather than a response to demonstrated harm, and it remains based on limited clinical evidence [290–292]. Beyond discrete adverse events, longer-term safety considerations encompass changes in body composition and treatment durability. A substantial fraction of GLP-1RA-associated weight loss reflects reductions in lean mass, representing a weight-dependent effect, raising particular concern in older adults and individuals with sarcopenic obesity. These observations underscore the importance of resistance exercise, adequate protein intake, and individualized risk mitigation strategies as components of long-term therapy [55, 57, 58]. In addition, discontinuation of treatment is frequently followed by weight regain and attenuation of metabolic benefits, reframing safety as a chronic disease management issue rather than a short-term tolerability question [60, 293]. Finally, system-level factors, including high cost, supply instability, and inequitable access, represent indirect yet clinically relevant safety considerations. Treatment interruptions and inconsistent dosing driven by these constraints may undermine both effectiveness and real-world safety [294–296]. Diabetes-specific nuances also persist, including signals for diabetic retinopathy complications observed with semaglutide in early outcome trials, likely related to rapid glycemic improvement. Ongoing studies are expected to define the long-term ophthalmic risk profile better [63, 64, 297]. In this context, many safety considerations of GLP-1RAs, particularly those related to body composition and metabolic adaptation, are closely linked to weight-dependent mechanisms. The overall safety profile should therefore be interpreted within the broader context of long-term, weight-driven metabolic remodeling. Future research directions for GLP-1RAs Despite the rapid clinical expansion of GLP-1RAs from glucose-lowering therapies to widely prescribed agents for obesity and cardiometabolic risk reduction, several unresolved questions continue to define the limits of current evidence and should shape future research priorities. Chief among these is the long-term benefit–risk profile of sustained GLP-1 RA therapy. Although short- and medium-term trials consistently demonstrate meaningful weight loss and metabolic improvement, the durability of these effects over extended time horizons, and their influence on hard outcomes such as cardiovascular events, malignancy, frailty, and all-cause mortality, remain insufficiently characterized. Longitudinal studies with prolonged follow-up are therefore essential, particularly in non-diabetic populations exposed to higher anti-obesity doses, where long-term safety data are most limited [167]. Future research priorities reflect current gaps in long-term clinical outcomes, mechanistic understanding, and real-world effectiveness. A related, unresolved challenge is disentangling weight-dependent from weight-independent effects of GLP-1RAs across organ systems. Many reported extra-glycemic benefits and adverse outcomes, including those involving bone health, psychiatric endpoints, gallbladder disease, and retinopathy, may reflect the downstream consequences of rapid or sustained weight loss rather than direct receptor-mediated actions. Addressing this distinction will require carefully designed studies incorporating active comparators with matched weight trajectories, mediation analyses, or trajectory-adjusted models capable of separating metabolic from pharmacologic effects [61]. This distinction is central to interpreting multisystem effects. Formulation development represents another area with important clinical and translational implications. Oral GLP-1 RA therapies may expand access and improve adherence, but they also introduce new uncertainties. Oral semaglutide has demonstrated efficacy in diabetes and obesity, with cardiovascular safety initially supported by PIONEER-6 and subsequently reinforced by the SOUL trial, which reported a reduction in MACE in high-risk individuals with type 2 diabetes [65, 298, 299]. In parallel, non-peptide oral agents such as orforglipron have shown promising glycemic and weight-related effects in phase 2 studies [300, 301]. Whether these advantages translate into superior long-term adherence, tolerability, or real-world effectiveness compared with injectable formulations remains unclear and warrants head-to-head comparative effectiveness studies incorporating patient-reported outcomes [302, 303]. Combination strategies constitute an especially active research frontier, reflecting efforts to amplify efficacy while potentially offsetting class-specific limitations. Dual incretin agonists such as tirzepatide have been associated with greater weight loss and glycemic improvement than GLP-1RAs alone, plausibly through complementary metabolic pathways [47]. Early-phase studies of triple agonists targeting GLP-1, GIP, and glucagon receptors, including retatrutide, suggest even greater weight-reducing potential based on early-phase evidence, although long-term safety and tolerability remain to be established [51]. Additional combinations, pairing GLP-1RAs with SGLT-2 inhibitors, amylin analogues, or centrally acting appetite modulators, may further enhance therapeutic profiles, yet optimal sequencing, dosing strategies, and patient selection are largely unexplored and require systematic investigation [304, 305]. Precision medicine approaches are likely to become increasingly relevant as clinical use broadens. Substantial interindividual variability exists in weight loss, metabolic response, tolerability, and adverse-event risk. Future research should prioritize the identification of genetic, epigenetic, metabolic, and microbiome-derived biomarkers capable of predicting both benefit and harm, thereby enabling more individualized treatment strategies. Such efforts may be particularly important for identifying patients at elevated risk of psychiatric adverse effects, excessive lean mass loss, or early treatment discontinuation [306, 307]. However, clinically validated predictive biomarkers are currently lacking. Beyond biological and clinical considerations, health-economic questions represent a critical and often underappreciated research priority. The expanding use of GLP-1RAs raises concerns regarding affordability, sustainability, and equitable access. Robust cost-effectiveness analyses are needed to balance high acquisition costs against potential long-term savings from reduced obesity-related morbidity, improved functional capacity, and enhanced quality of life. Policy-relevant strategies, including targeted prescribing frameworks, alternative delivery systems, or eventual generic availability, may be required to support population-level implementation without compromising healthcare system viability [308]. At the mechanistic and translational level, ongoing research aims to refine next-generation GLP-1–based therapies. Greater resolution of tissue-specific and context-dependent GLP-1 receptor signaling, including the contribution of β-arrestin–mediated pathways, may support the development of biased agonists with improved therapeutic windows and fewer adverse effects, although clinical translation remains uncertain [9]. In parallel, expanding investigation into neurological and neurodegenerative conditions, such as Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and traumatic brain injury, represents a biologically compelling but as yet unproven direction that will require rigorously designed disease-modifying trials rather than extrapolation from metabolic outcomes alone [9]. Taken together, future research on GLP-1RAs must move beyond short-term weight loss and glycemic endpoints toward integrated, long-horizon strategies that address mechanistic specificity, durability of benefit, long-term safety, individualized response, and real-world implementation. Only through such an approach can the role of GLP-1RAs as sustained, multi-system therapies be defined with appropriate scientific rigor and restraint [9, 167]. Future studies should also prioritize mechanistic designs capable of distinguishing weight-dependent from weight-independent effects across organ systems. Conclusions GLP-1Ras have evolved from glucose-lowering therapies into cornerstone agents within contemporary cardiometabolic medicine. Robust evidence from large randomized trials, meta-analyses, and real-world studies consistently supports clinically meaningful weight loss, cardiovascular risk reduction, and kidney protection in both diabetic and non-diabetic populations, establishing benefits that extend beyond glycemic control alone. The magnitude and durability of weight reduction achieved with agents such as semaglutide and tirzepatide have reshaped pharmacologic obesity management and translated into improvements in obesity-related comorbidities, including OSA and metabolic liver disease. Nevertheless, challenges such as lean mass loss, weight regain following treatment discontinuation, and the need for long-term maintenance strategies underscore obesity as a chronic condition requiring sustained and individualized therapy. These benefits are predominantly driven by weight-dependent mechanisms. Beyond established cardiometabolic indications, accumulating experimental and translational data suggest broader biological actions of GLP-1RAs, including effects on immune regulation, skeletal biology, and neuroprotection. However, clinical evidence in these domains remains heterogeneous and largely exploratory, and definitive disease-modifying effects have not yet been confirmed. Accordingly, such findings should be interpreted as biologically plausible signals rather than established therapeutic indications. Most evidence in these areas is derived from preclinical or early-phase studies. Across organ systems, the effects of GLP-1RAs can be broadly interpreted within a framework of weight-dependent, mixed, and weight-independent mechanisms. Overall, the expanding clinical footprint of GLP-1RAs reflects a convergence of robust clinical efficacy and biologically plausible mechanisms within cardiometabolic disease. Their long-term role beyond these indications will depend on sustained safety data, durability of benefit, and adequately powered, disease-specific trials designed around clinically meaningful endpoints. Future research should prioritize distinguishing mechanistic pathways, particularly the relative contribution of weight-dependent versus weight-independent effects.